No data to show
OTCM
RZONF
Market cap7mUSD
May 23, Last price
0.16USD
Name
GeneTether Therapeutics Inc
Chart & Performance
P/E
—
P/S
—
EPS
—
Div Yield, %
—
Shrs. gr., 5y
—
Rev. gr., 5y
%
Revenues
0k
Net income
-688k
L-59.82%
CFO
-465k
L-60.53%
Profile
GeneTether Therapeutics Inc., a genetic medicines company, focuses on developing gene editing therapies to enhance the efficiency of genome editing technologies. It is developing gene therapies for the treatment of patients with rare and monogenic kidney and skin diseases. The company was founded in 2018 and is based in Kelowna, Canada.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | |
| Income | |||||
Revenues | |||||
Cost of revenue | 747 | 1,717 | |||
Unusual Expense (Income) | |||||
NOPBT | (747) | (1,717) | |||
NOPBT Margin | |||||
Operating Taxes | (2) | ||||
Tax Rate | |||||
NOPAT | (747) | (1,715) | |||
Net income | (688) -59.82% | (1,713) 4.60% | |||
Dividends | |||||
Dividend yield | |||||
Proceeds from repurchase of equity | 2,997 | ||||
BB yield | |||||
| Debt | |||||
Debt current | |||||
Long-term debt | |||||
Deferred revenue | |||||
Other long-term liabilities | 87 | ||||
Net debt | (1,364) | (1,796) | |||
| Cash flow | |||||
Cash from operating activities | (465) | (1,178) | |||
CAPEX | |||||
Cash from investing activities | |||||
Cash from financing activities | 2,997 | ||||
FCF | (695) | (1,776) | |||
| Balance | |||||
Cash | 1,364 | 1,796 | |||
Long term investments | |||||
Excess cash | 1,364 | 1,796 | |||
Stockholders' equity | (261) | 380 | |||
Invested Capital | 1,633 | 1,476 | |||
ROIC | |||||
ROCE | |||||
| EV | |||||
Common stock shares outstanding | 46,412 | 48,377 | |||
Price | |||||
Market cap | |||||
EV | |||||
EBITDA | (747) | (1,717) | |||
EV/EBITDA | |||||
Interest | 2 | ||||
Interest/NOPBT | |||||